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June 20121834 Abstractsature on intra-abdominal reversible adverse outcomes and permanent ad-
verse outcomes after DTA and TAAA open repair. This was a retrospective
review of patients at the authors’ institution who underwent open DTA and
TAAA repair between January 2002 and December 2008. The authors
included relevant preoperative, intraoperative, and postoperative data and
performed a propensity score-matched analysis. Data sufficient to permit
analysis were available for 240 of 262 patients, with 90 suitable for the
propensity-matched study. Reversible adverse outcomes included analysis
for renal failure, temporary hemodialysis, and liver failure. Permanent ad-
verse outcomes identified were permanent hemodialysis, 30-day mortality,
and paraplegia. The 30-day mortality was 7.1% (17 of 240). Reversible
adverse outcomes developed in 40.8% of patients and permanent adverse
outcomes in 10%. Propensity score analysis identified decreased odds of
developing reversible adverse outcomes in patients undergoing DHCA
(odds ratio, 0.32: 95% confidence interval, 0.12-0.85). Rates of acute renal
failure (22% vs 46.4%, P  .03) and liver failure (17.8% vs 34.3%, P  .04)
were lower in patients who underwent DHCA compared with the non-
DHCA group.
Comment:Regionalization of complex procedures makes sense, and in
vascular surgery, open thoracoabdominal surgery should be regionalized.
Patients may not like to travel for care, but they do not want to die or
become paralyzed as a result of their care either. Only a small minority of
hospitals have the patient volume, technical expertise, and institutional
resources to really do open TAAA surgery well. That number will be even
smaller for those using DHCA to facilitate TAAA surgery. If DHCA is truly
a useful adjunct in TAAA surgery, it is still another reason to argue for
regionalization of TAAA surgery.
Combination Oral Antiplatelet Therapy may Increase the Risk of
Hemorrhagic Complications in Patients With Acute Ischemic Stroke
Caused by Large Artery Disease
Itabashi R, Mori E, Furui E, et al. Thromb Res 2011;128:541-6.
Conclusion: The incidence of hemorrhagic complications is likely
increased in patients with acute ischemic stroke secondary to large artery
disease who are treated with combination antiplatelet therapy.
Summary: It is recommended oral antiplatelet therapy be administered
immediately after acute ischemic stroke to prevent recurrence and progres-
sion of stroke as well as to prevent other vascular events. It is known that
monotherapy with aspirin does not reduce stroke progression (MarkusHS et
al, Circulation 2005;111:2233-40). However, it is thought that combina-
tion antiplatelet therapy, such as that provided by clopidogrel and aspirin,
may have a role in reducing stroke progression in patients with stroke
secondary to large artery disease (Wong KS et al, Lancet Neurol 2010;9:
489-97; Diener HC et al, Lancet 2004;64:331-7). There is an increased risk
of hemorrhagic complications with long-term secondary preventative ther-
apy with combination antiplatelet agents (Bhatt DL et al, N Engl J Med
2006;354:1706-17; Gasparyan AY et. al, J Am Coll Cardiol 2008;5:1829-
43). The risk of combination antiplatelet therapy in the short-term treat-
ment of acute stroke is not well understood. This retrospective study
evaluated bleeding complications associated with antiplatelet therapy in
patients with ischemic stroke secondary to large artery disease who were felt
to be at high risk for stroke recurrence or progression. The authors reviewed
1335 consecutive patients admitted 7 days of an ischemic stroke or
transient ischemic attack between April 2005 and November 2009. There
were 167 patients with 50% stenosis or occlusion of a culprit major vessel
treated with antiplatelet agents 48 hours of admission. Hemorrhagic
complications were classified according to the bleeding severity index. Of the
167 patients studied, 108 were treated with combination antiplatelet agents
and 59 with one antiplatelet agent. Three major and 11 minor hemorrhagic
complications occurred in 14 patients. All major hemorrhagic complications
occurred in patients administered combination antiplatelet therapy. The
proportion of patients receiving combination agents was higher in those
with significant hemorrhagic complications. Older age and receiving com-
bination antiplatelet agents were independent predictors of a significant
in-hospital hemorrhagic complication.
Comment: Despite the retrospective study design and the small num-
ber of end points, this study raises questions about the overall safety of
combination antiplatelet therapy in the treatment of ischemic stroke caused
by large artery disease. It is important to keep inmind that antiplatelet agents
work through different mechanisms of action. It is therefore not surprising
that the untoward effects of the sum may be greater than that observed with
individual agents. This study will help determine appropriate statistical
power for larger more definitive clinical trials with respect to end points and
safety monitoring.
Defining Perioperative Mortality after Open and Endovascular Aortic
Aneurysm Repair in the US Medicare Population
Schermerhorn ML, Giles KA, Sachs T, et al. J Am Coll Surg 2011;212:349-
55.
o
iConclusions: Comparisons of in-hospital mortality overestimate the
enefit of endovascular abdominal aortic aneurysm (AAA) repair (EVAR)
ompared with 30-day or combined 30-day and in-hospital mortality. The
uration of highest mortality risk extends longer for open repair, and the
otal mortality impact of AAA repair is not realized until 3 months after
epair.
Summary: Perioperative mortality is an important measure of quality
or surgical procedures. Definitions of the “perioperative” period differ.
erioperative mortality may be defined as death during the initial hospital-
zation, 30 days of surgery, or all deaths 30 days plus any deaths 30
ays that occur before hospital discharge. In addition, ongoing risks due to
urgery may persist 30 days and beyond hospital discharge. The authors
nvestigated the affects and implications of various methods of calculating
perioperative mortality” with respect to EVAR vs open AAA repair. They
sed propensity-scoring models to create matched cohorts of U.S. Medicare
eneficiaries undergoing EVAR (n  22,830) or open repair (n  22,830)
rom 2001 to 2004. Perioperative mortality was calculated using in-hospital
ortality, 30-day mortality, and combined 30-day and in-hospital mortality.
he authors also calculated biweekly interval death rates for 12 months to
efine the duration of increased risk for death after AAA repair. In-hospital,
0-day, and combined 30-day and in-hospital mortality for open repair and
VAR were 4.6% vs 1.1%, 4.8% vs 1.6%, and 5.3% vs 1.7%, respectively.
bsolute differences in mortality were similar at 3.5%, 3.2%, and 3.7%.
elative rates of death (95% confidence interval) were 4.2 (3.6-4.8), 3.1
2.7-3.4), and 3.2 (2.8-3.5). Biweekly interval death rates were highest
uring the first month after EVAR (0.6%) and during the first 2.5 months
0.5% to 2.1%) after open repair. After 2.5 months, rates were similar for
oth repairs (0.5%) and were stabilized after 3 months. The 90-day
ortality rates were 7.0% for open repair and 3.2% for EVAR.
Comment: The main point here is not that AAA patients undergoing
VAR or open repair continue to experience procedure-related morbidity
eyond their hospital stay or the first 30 postoperative days. We all have seen
ate procedure-related complications in our patients. However, it seems we,
s surgeons, by focusing on 30-day and/or in-hospital morbidity and
ortality, underestimate in the surgical literature the effect of our proce-
ures on our patients. Perhaps, for procedures of greater magnitude, such as
AA repair, journal editors should encourage reporting of periprocedural
orbidity and mortality data out to 3 months.
icroembolization During Carotid Artery Stenting in Patients With
igh-Risk, Lipid-Rich Plaque: A Randomized Trial of Proximal Vs
istal Cerebral Protection
ontorsi P, Caputi L, Galli S, et al. J Am Coll Cardiol 2011;58:1656-63.
Conclusion: In patients undergoing carotid artery stenting (CAS) who
ave a lipid-rich plaque, the use of a proximal cerebral protection system
uring CAS results in lower numbers of microemboli compared with distal
erebral protection with a filter wire during CAS.
Summary: It is well recognized distal cerebral protection during CAS
oes not fully prevent embolic complications. The reasons for this are
nclear but may include unprotected crossing of the lesion, incomplete
pposition of the device to the arterial wall, emboli smaller than the filter
ore size, and loss of debris with filter recapture. Proximal endovascular
cclusion using balloons to occlude the external carotid artery and the
ommon carotid artery, resulting in blood flow arrest in the internal carotid
rtery during CAS, may be a better technique for providing cerebral protec-
ion. Although the proximal occlusion technique has several potential draw-
acks, including patient intolerance to occlusion, potential dissection of the
xternal carotid artery, and need for a larger sheath (8F/9F), the potential to
ecrease microembolic events during CAS is intriguing. Increased numbers
f microembolic signals (MES) detected with transcranial Doppler (TCD)
ave been associated with a greater prevalence of silent ischemic cerebral
esions detected on post-CAS magnetic resonance diffusion-weighted imag-
ng (DWI). The significance of silent DWI-detected ischemic lesions after
arotid intervention is unknown, but there is some suggestion they could be
ssociated with late cognitive decline. Patients with lipid-rich plaque appear
lso to be at higher risk because they have an increased prevalence of
WI-detected lesions after CAS. The authors studied 53 consecutive pa-
ients with lipid-rich plaque undergoing CAS who were randomized to a
roximal protection device (n  26) or distal protection (n  27) with a
lter wire. MES were assessed with TCD during crossing of the lesion,
efore dilation, stent crossing, stent deployment, stent dilation, and during
evice retrieval/deflation. DWI was performed before CAS and after CAS at
8 hours and 30 days. Patients treated with the proximal cerebral protection
evice had a higher rate of ulcerated plaque than those whose cerebral
rotection was provided with a filter wire (35% vs 7.4%; P  .019).
ompared with the filter wire, the proximal cerebral protection device
educed the mean number of TCD-detected MES during crossing of the
esion (18 vs 2, P .001), stent crossing (23 vs 0), stent deployment (30 vs
), stent dilation (16 vs 0), and the total number of MES detected (93 vs
6). Multivariable analysis showed the type of cerebral protection was the
nly independent predictor of totalMES. There was no significant difference
n the number of patients with new post-CAS embolic lesions in the
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Volume 55, Number 6 Abstracts 1835proximal protection group (2 of 14, 14%) compared with the filter wire
group (9 of 21, 43%).
Comment: About all we can currently say is that microemboli occur
during carotid interventions. However, microemboli also clearly occur in
patients with asymptomatic carotid disease who are not undergoing any
carotid procedure. Because these emboli in nonprocedural asymptomatic
patients can be detected with only a couple of hours of routine TCD
monitoring, it logically follows the cumulative number of emboli associated
with a 2-hour individual procedure is probably relatively small compared
with the number that have likely occurred over the months or even years of
the presence of the carotid stenosis before treatment. Perhaps the brain
tolerates boluses of emboli less well than more emboli occurring over a
longer time span?
Safety and efficacy of Dalcetrapib on atherosclerotic disease using novel
non-invasive multimodality imaging (dal-PLAQUE): a randomised
clinical trial
Fayad ZA, Mani V, Woodward M, et al. Lancet 2011;378:154-9
Conclusion: Dalcetrapib, a cholesterol esterase transfer inhibitor,
shows no evidence of pathologic effects on the arterial wall and may have
beneficial effects, such as increased high-density lipoprotein cholesterol
(HDL-C) and reduction in total vessel enlargement over 24 months.
Summary: It may be possible to reduce atherosclerotic plaque burden
by raising HDL-C. The importance of elevating HDL-C levels has been
demonstrated in statin-treated patients where low HDL-C plasma concen-
trations continue to be an independent risk factor for cardiovascular events,
with high HDL-C levels associated with reduced plaque progression and
reduced frequency of cardiovascular events (Jafri H et al, Ann Intern Med
2010;153:800-8; Wei L et al, Heart 2006;92:746-51). HDL-C can be
increased using drugs that act on cholesterol ester transfer protein (CETP).
The CETP inhibitor torcetrapib was found to effectively increase HDL-C
but was associated with increased mortality, thought to be secondary to
off-target effects such as increased blood pressure and increased vascular
inflammation (Niesor EJ et al, J Lipid Res 2010;51:3443-54). Dalcetrapib is
an inhibitor of CETP activity that also increases HDL-C. It has not been
associated with clinically relevant increases in blood pressure, and preclinical
experience in rodent models shows a decrease in atherosclerosis with Dalce-
trapib (Okamoto H et al, Nature 2000;406:203-7). The authors sought to
c
tetermine, using magnetic resonance imaging (MRI) and positron-emission
omography (PET)/computed tomography (CT) scanning, the effects of
alcetrapid on plaque morphology, progression and regression of athero-
clerosis, and plaque inflammation. The primary goals of this study were to
se this dual-imaging approach to determine whether Dalcetrapid results in
n increase in atherosclerotic plaque progression or vascular inflammation
ompared with placebo. This was a phase II double blind, multicenter,
tudy. Study participants were aged 18 to 75 years and were not thought to
e at high risk for coronary artery disease. They were randomly assigned 1:1
o Dalcetrapib (600 mg/d) or placebo for 24 months. Patients and investi-
ators were masked to treatment. Coprimary end points were MRI-assessed
ndices (total vessel area, wall area, wall thickness, and normalized wall index
average carotid]) after 24 months and 18F-flurodeoxyglucose PET/CT
ssessment of arterial inflammation within an index vessel (right carotid, left
arotid or ascending thoracic aorta) after 6 months. No-harm boundaries
ere established before unblinding of the trial, and analysis was by intention
o treat. There were 189 patients screened and 130 randomized to placebo
n  66) or Dalcetrapib (n  64). Confidence intervals for the coprimary
RI and PET/CT end points demonstrated that the no-harm boundary or
dverse changes was numerically lower in the Dalcetrapid group than in the
lacebo group. MRI-derived change in total vessel area was reduced in
atients given Dalcetrapid compared with those with placebo after 24
onths. The absolute change from baseline relative to placebo was –4.01
m2 (90% confidence interval, 7.23-0.80; nominal P .04). Carotid artery
nalysis showed a 7% reduction in the most diseased segment (target-to-
ackground ratio in the Dalcetrapid vs placebo groups, –7.3; 90% confi-
ence interval, –13.0 to –0.8).
Comment: Torcetrapib, the previous “hot” drug in this class of
edications to raise HDL-C, was associated with prohibitive off-target side
ffects, but Dalcetrapib, the subject of this article, apparently is not; at least
ver the duration of the study. Improving HDL-C levels therefore remains
possible mechanism for treatment or even prevention of atherosclerosis
hrough modulation of the activity of CETP. The patients in this study were
ot at particularly high risk of atherosclerotic events, and there was insuffi-
ient power for assessment of clinical end points in this trial. Clinical end
oints are currently being assessed in two ongoing trials. Ultimately, al-
hough it is biologically interesting to potentially reverse atherosclerosis,
linical trials will determine the role of increasing HDL-C through medica-
ion administration in the treatment of atherosclerosis.
